NCT05714345View on ClinicalTrials.gov

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

February 20, 2024

Study Completion Date

October 31, 2029

Conditions
Relapsed/Refractory Large B Cell Lymphoma
Interventions
BIOLOGICAL

ALLO-647

ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

DRUG

Fludarabine

Chemotherapy for lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

GENETIC

ALLO-501A

ALLO-501A is an allogeneic CAR T cell therapy targeting CD19

Trial Locations (2)

1090

Universitair Ziekenhuis Brussel, Brussels

40202

University of Louisville James Graham Brown Cancer Center, Louisville

Sponsors
All Listed Sponsors
lead

Allogene Therapeutics

INDUSTRY

NCT05714345 - Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy | Biotech Hunter | Biotech Hunter